pentobarbital will lessen the extent or effect of cobimetinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Prevent coadministration. Potent or reasonable CYP3A inducers could minimize cobimetinib systemic exposure by >eighty% and lessen its efficacy.In January 2016, a health care provider who had been treating Erica